Sutro Biopharma Inc expected to post a loss of 62 cents a share - Earnings Preview

Sutro Biopharma

03/03/2023 14:23

* Sutro Biopharma Inc  STRO.OQ   STRO.O  is expected to show
a
rise in quarterly revenue when it reports  results on March 6
(estimated). 
    * The South San Francisco California-based  company is
expected to
report  a 35.9% increase in revenue to $14.479 million from
$10.65 million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Sutro Biopharma Inc
is
for a loss of 62 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sutro
Biopharma
Inc is $20​, above​ its last closing price of $5.75. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.75       -0.74      -0.37     Beat    49.9
 Jun. 30 2022  -0.43       -0.46      -0.55     Missed  -19.2
 Mar. 31 2022  -0.77       -0.76      -0.84     Missed  -10.9​
 Dec. 31 2021  -0.70       -0.69      -0.83     Missed  -20.5
 ​​Sep.        -0.65       -0.65      -0.67     Missed  -2.9
 30 2021                                                
 Jun. 30 2021  -0.41       -0.41      -0.13     Beat    68.6​
 Mar. 31 2021  -0.63       -0.60      -0.66     Missed  -9.4
 Dec. 31 2020  -0.44       -0.57      -1.48     Missed  -159.6
 This summary was machine generated March 3 at 14:23 GMT.  All
figures in US dollars  unless otherwise stated